title: [Hyperuricemia in hematological disorders].
abstract: Hyperuricemia is a common manifestation in various hematological disorders such as hemolytic anemias, megaloblastic anemia malignant lymphomas and leukemias. Tumor lysis syndrome (TLS) is a serious complication consists of hyperuricemia, hyperkalemia, hyperphosphatemia and hypocalcemia due to massive cell lysis, which occurs shortly after the onset of chemotherapy or radiotherapy for acute leukemias and malignant lymphomas. Acute renal failure may develop due to uric acid nephropathy. The risk factors of TLS are heavy tumor cell burden, rapid cell turn over rate and renal involvement of neoplastic cells. To prevent and control TLS, adequate intravenous hydration to keep patient's urine volume, alkalization of urine by sodium bicarbonate and inhibition of uric acid production by high dose allopurinol is recommended.
authors.affiliation: Division of hematology, Kanto-Rosai Hospital.
authors.forename: J
authors.initials: J
authors.lastname: Iwata
mesh_terms: D001853:Bone Marrow / Q000473:pathology; D001855:Bone Marrow Diseases / Q000209:etiology; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology; D009336:Necrosis; D015275:Tumor Lysis Syndrome / Q000209:etiology*; D014527:Uric Acid / Q000097:blood*
chemical_list: D014527:Uric Acid